MétaCan
Menu
Back to cohort
Record W4406697925 · doi:10.1093/ecco-jcc/jjae190.1351

P1177 Factors Driving Persistence to First-Line Advanced Therapies in Inflammatory Bowel Disease – A Real-World Study

2025· article· en· W4406697925 on OpenAlexaff
Giovanni Santacroce, Marco Vincenzo Lenti, Federica Lepore, Francesco Mordà, A Lo Bello, Nicola Aronico, Caterina Mengoli, Mariangela Delliponti, Antonio Di Sabatino

Bibliographic record

VenueJournal of Crohn s and Colitis · 2025
Typearticle
Languageen
FieldMedicine
TopicPharmaceutical studies and practices
Canadian institutionsUniversity Hospital Foundation
Fundersnot available
KeywordsMedicineInflammatory bowel diseasePersistence (discontinuity)DiseaseCrohn's diseaseUlcerative colitisInternal medicineGastroenterologyIntensive care medicine

Abstract

fetched live from OpenAlex

Abstract Background Advanced therapies, including biologics and small oral molecules, are the mainstay of inflammatory bowel disease (IBD) management. Nonetheless, factors driving drug persistence - defined as the duration from initiation to discontinuation of a therapy- remain unclear. This study aimed to evaluate the persistence of first-line advanced therapies in a real-word IBD cohort and identify factors influencing it. Methods Demographic and clinical data from IBD patients who initiated first-line advanced therapies after 2010 at the San Matteo Hospital Foundation were retrospectively collected in September 2024. Persistence and discontinuation, due to failure or other reasons, were recorded. Differences in persistence probability between therapies were analysed using the log-rank test. Univariate (Fisher’s exact test for categorical variables and t-test or Mann-Whitney for continuous variables) and multivariate (logistic regression) analyses were conducted to assess factors influencing persistence versus discontinuation due to failure. Results Among the 274 recruited patients (median age 42.5 years; F/M 119/155; 146 with Crohn’s disease (CD) and 128 with ulcerative colitis), 159 (58%) started infliximab, 76 (28%) adalimumab, 26 (9.5%) vedolizumab, 3 (1%) ustekinumab, 3 (1%) Janus-kinase inhibitors and 7 (2.5%) other advanced therapies as first-line treatment. Persistence was observed in 141 patients (51.5%), while 70 (26%) discontinued due to failure, 19 (6.9%) due to allergy/intolerance, 18 (6.6%) due to remission, 2 (0.7%) due to immunogenicity, and 24 (8.8%) for other/unknown reasons. No significant difference in drug persistence was observed between therapies (p=0.11). Univariate analysis identified CD phenotype (p<0.01), disease duration (p=0.01), concomitant mesalamine (p<0.01) or steroids (p<0.01), and therapy optimisation (p<0.01) as factors influencing persistence. A trend toward higher faecal calprotectin levels was observed in the discontinuation group (550 vs 385 mg/kg, p=0.09), while subcutaneous administration showed a slightly higher persistence rate (45% vs 33%, p=0.11). Multivariate analysis confirmed the CD phenotype as factor associated with higher persistence, while therapy optimisation was identified as a risk factor for discontinuation. Conclusion While persistence rates were similar across therapies, multiple factors influence persistence or discontinuation, offering potential guidance for optimising IBD management.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame distilled prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.

metaresearch head score (Codex)0.000
metaresearch head score (Gemma)0.000
Version: codex-gemma-dda1882f352aValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: Observational
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.036
Threshold uncertainty score0.332

Codex and Gemma teacher scores by category

CategoryCodexGemma
Metaresearch0.0000.000
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0000.000
Bibliometrics0.0000.000
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.000
Insufficient payload (model declined to judge)0.0000.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.035
GPT teacher head0.356
Teacher spread0.321 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one teacher head, not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2025
Admission routes1
Has abstractyes

Explore more

Same venueJournal of Crohn s and ColitisSame topicPharmaceutical studies and practicesFrench-language works237,207